Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...
Daily6d
Phase 2b QUALITY Trial: Enobosarm Significantly Reduces Lean Mass Loss in Patients on Semaglutide
Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...
MM&M6d
Rx Rundown: Merck, Biogen, Pfizer and more
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...